Cambrex Completes FDA Inspection
PTSM: Pharmaceutical Technology Sourcing and Management
FDA completes an inspection of Cambrex's API manufacturing facility in Charles City, Iowa.
Cambrex reported that FDA completed an inspection of Cambrex’s API manufacturing facility in Charles City, Iowa. The inspection found the site to be compliant with the principles and guidelines of GMP and no Form 483 observations were issued. FDA authorities inspected the facility from July 31 to August 2, 2013.
This follows successful inspections at Charles City made previously by FDA in March 2010 and February 2012, neither of which resulted in any issued 483 observations, the Korean FDA in January 2012 and the Medicines and Healthcare Products Regulatory Agency of the UK October 2011, after which a GMP certificate for a drug product intermediate was issued.
Source: Cambrex
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
